Drugs / Autologous Anti-CD83 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06871410 | Feb 2026 → Apr 2028 expected | acute myeloid leukemia | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Anti-CD83 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06871410 ↗ |
| Action | Deplete | “CD83 CAR T cells represent a new cell therapy to eliminate AML blasts” NCT06871410 ↗ |
| Modality | Cell therapy | “CD83 CAR T cells represent a new cell therapy” NCT06871410 ↗ |
| Route | Intravenous | “Patients then receive CD83 CAR T cells IV over 15 minutes on day 0.” NCT06871410 ↗ |